Needle-free demand Position Biora's BioJet platform as a transformative solution for patients and providers seeking needle-free, oral dosing of biologics, which aligns with growing patient-centric delivery trends and can attract partnerships with large pharma seeking better administration methods.

Biologic delivery focus Target biopharma segments developing proteins, antibodies, and complex biomolecules who need reliable oral delivery to expand administration routes, potentially unlocking collaborations for clinical programs and faster patient access.

Strategic funding momentum Leverage the recent capital raise and Frost Radar recognition to approach investors and strategic partners for co-development deals, licensing opportunities, and expansion financing to accelerate pipeline milestones.

California progress Highlight California progress and regulatory milestones to engage regional partners, contract manufacturers, and academia for pilot manufacturing, clinical trial support, and funding opportunities within a biotech-friendly ecosystem.

Growth through partnerships Emphasize the scalable delivery platform for diverse payloads to pursue co-development or in-licensing deals with mid-to-large pharma seeking innovative delivery platforms to differentiate their biologics portfolios.